Stockscreener 앱 받기
0.9984
0.16%
-0.0016
시간 외 거래:
.99
-0.0084
-0.84%
전일 마감가:
$1.00
열려 있는:
$1.01
하루 거래량:
2.06M
Relative Volume:
0.38
시가총액:
$291.56M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-3.6978
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+0.48%
1개월 성능:
-4.91%
6개월 성능:
+40.15%
1년 성능:
-22.00%
1일 변동 폭
$0.97
$1.01
1주일 범위
$0.931
$1.02
52주 변동 폭
$0.515
$1.40
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9984 | 280.01M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Secures $20 Million in Direct Offering with Janus Henderson - MSN
Ocugen Raises $20M in Registered Direct Offering with Warrants for Potential $30M Boost. - AInvest
Ocugen's $20M Funding Move: Strategic Capital Raise or Warning Signal? - AInvest
Ocugen's $20M Raise: A Calculated Gamble in the Gene Therapy Arms Race? - AInvest
Will Ocugen Inc. outperform the market in YEARPre-Earnings Rally Picks - kangso.co.kr
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants - Ocugen
Ocugen announces $20M registered direct offering of common stock, warrants - TipRanks
Ocugen's $20M Equity Raise and Warrant Offering: Strategic Capital Move or Dilution Risk? - AInvest
Ocugen raises $20 million in registered direct offering By Investing.com - Investing.com Australia
Ocugen raises $20 million in registered direct offering - Investing.com
Ocugen Raises $20M in Direct Offering of Common Stock and Warrants - AInvest
Ocugen Lands $50M Potential Financing Deal: Janus Henderson Backs Blindness Gene Therapy Pioneer - Stock Titan
Ocugen Highlights Gene Therapy Advances, Strategic Deals in Second Quarter Update - MSN
AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Releases Second Quarter 2025 Financial Results, Provides Business Update - VisionMonday.com
Ocugen Analyst Ratings: Bullish and Bearish Perspectives Amidst Price Target Changes - AInvest
Ocugen Reaffirms Buy Rating and $7.00 Price Target with Chardan Capital - AInvest
Ocugen, Inc. SEC 10-Q Report - TradingView
Can Ocugen Inc. Rally Enough to Break EvenSector Based Breakout Stock Forecast Issued - metal.it
How volatile is Ocugen Inc. stock compared to the marketExplosive wealth accumulation - Jammu Links News
What are the latest earnings results for Ocugen Inc.Accelerated financial growth - Jammu Links News
What makes Ocugen Inc. stock price move sharplyExceptional market positioning - Jammu Links News
Is Ocugen Inc. stock overvalued or undervaluedMaximize your gains with professional insights - Jammu Links News
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsGet real-time alerts on high-potential stocks - Jammu Links News
Should I hold or sell Ocugen Inc. stock in 2025Build a diversified portfolio for risk management - Jammu Links News
What institutional investors are buying Ocugen Inc. stockFree Stock Market Real-Time Monitoring - Jammu Links News
Ocugen Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
What are the technical indicators suggesting about Ocugen Inc.Free Stock Market Mentorship - Jammu Links News
Is it the right time to buy Ocugen Inc. stockSuperior returns - Jammu Links News
What are Ocugen Inc. company’s key revenue driversGet alerts on the hottest stocks daily - Jammu Links News
What catalysts could drive Ocugen Inc. stock higher in 2025Unstoppable trading performance - Jammu Links News
What markets is GWH.WS expanding into Is Ocugen Inc. stock a good long term investment option - Jammu Links News
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Ocugen outlines three licensing applications and 2026 commercialization plans while advancing gene therapy trials - MSN
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Evaluating Ocugen's Q2 Earnings and Strategic Progress: Clinical Milestones and Capital Efficiency as Catalysts for Long-Term Value Creation in Biotech Investing - AInvest
Ocugen Advances Gene Therapy for Blindness with Strategic Deals and Clinical Progress - AInvest
Ocugen Secures Licensing Deal for OCU400 in Korea, Enhancing Business Presence and Shareholder Value - AInvest
Ocugen, Inc. (OCGN): A High-Risk, High-Reward Biotech Play in Gene Therapy - AInvest
Ocugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges - MSN
Ocugen: Q2 Earnings Snapshot - Chron
Ocugen Provides Business Update with Second Quarter 2025 Financial Results - ADVFN Brasil
Ocugen's Strategic Path to 2026 BLA Filings and Global Gene Therapy Leadership - AInvest
Ocugen's Q2 2025 Earnings Call: Unpacking Contradictions in Trial Timelines, Manufacturing, and Strategic Direction - AInvest
Is Ocugen Inc. a growth stock or a value stockFree Stock Growth Plan For Smart Trading - Jammu Links News
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):